Skip to main content
SpringerLink
Log in

Dapagliflozin dominated by metformin for T2DM in China

  • Epidemiology clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Nian H, et al. Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. Cost Effectiveness and Resource Allocation : 28 Feb 2020. Available from: URL: https://doi.org/10.1186/s12962-020-00208-w

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dapagliflozin dominated by metformin for T2DM in China. PharmacoEcon Outcomes News 848, 5 (2020). https://doi.org/10.1007/s40274-020-6618-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6618-7

Search

Navigation